Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | QPCT | Q16769 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044091 | 0.90 | QPCT (0.39) | HSD11B1QPCTQPCTL | |
| SCHEMBL3050325 | 0.88 | HSD11B1 (0.33) | HSD11B1QPCT | |
| SCHEMBL3052845 | 0.86 | QPCT (0.35) | HSD11B1QPCTPOLBCCR2 | |
| Trifluoroacetic Acid SCHEMBL3040336 | 0.80 | SMO (0.44) | QPCTSMOMTNR1AMTNR1B | |
| SCHEMBL3050607 | 0.79 | HSD11B1 (0.33) | HSD11B1QPCT | |
| SCHEMBL3048636 | 0.77 | HSD11B1 (0.33) | HSD11B1QPCT | |
| SCHEMBL3043808 | 0.77 | POLB (0.33) | HSD11B1QPCTPOLB | |
| SCHEMBL1875561 | 0.76 | HSD11B1 (0.33) | HSD11B1QPCT | |
| SCHEMBL1874617 | 0.76 | QPCT (0.34) | HSD11B1QPCT | |
| Hydrochloric Acid SCHEMBL3034632 | 0.75 | ABCB1 (0.34) | HSD11B1QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | HSD11B1 1860/4885QPCT 1796/4885CNR1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.